Clinical trials: Pancreatic Cancer Stage II
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with…
- Conditions
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Trial name
- NCT02912949
- Testing
- zenocutuzumab (MCLA-128)
- Where
- 64 sites in United States, Austria and 16 more
- Volunteers
- 250 people
- Sponsor
- Partner Therapeutics, Inc.
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01234935
- Testing
- dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- 17 sites in United States
- Volunteers
- 8 people
- Sponsor
- Translational Oncology Research International
Pancreatic Cancer Non-resectable
Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
This is a Phase II, multicenter, randomized controlled trial to assess the efficacy of Stereotactic Body Radiotherapy (SBRT) in combination with maintenance therapy in patients with advanced pancreatic cancer.
- Trial name
- NCT07600268
- Testing
- Stereotactic Body Radiotherapy (SBRT) with maintenance therapy, Maintenance therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shandong Cancer Hospital and Institute
Metastatic Pancreatic Cancer
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.
- Trial name
- NCT05929885
- Testing
- Low Dose OXIRI (LD-OXIRI)
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus…
- Trial name
- NCT07238283
- Testing
- Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or…
- Conditions
- KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03040986
- Testing
- Laboratory Biomarker Analysis, Selumetinib Sulfate
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Pancreatic Cancer
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients.
- Trial name
- NCT03392571
- Testing
- NGC-Triple regimen
- Sponsor
- Pancreatic Cancer Research Team
Bladder Cancer, Cervical Cancer
Bupropion in Helping Adults Stop Smoking
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00534001
- Testing
- bupropion hydrochloride
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer, Unresectable Pancreatic Cancer
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer…
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
- Trial name
- NCT05251038
- Testing
- Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU)
- Where
- United States
- Sponsor
- Devalingam Mahalingam
Carcinoma, Pancreatic Ductal
Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy or in combination with capecitabine or…
- Trial name
- NCT01394120
- Testing
- Targeted Therapy Tailored Treatment, Standard Chemotherapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Sofia Perea, Director Clinical Trials Unit.
Pancreatic Cancer
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
- Trial name
- MASTERPLAN (NCT04089150)
- Testing
- Stereotactic Radiotherapy (SBRT), mFOLFIRINOX, Gemcitabine + Nab-paclitaxel
- Where
- 11 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT04821284
- Testing
- Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil
- Where
- 2 sites in United States, Norway
- Volunteers
- 120 people
- Sponsor
- Flemming Forsberg
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body.
- Trial name
- NCT04191421
- Testing
- Siltuximab, Spartalizumab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Emory University
Advanced Solid Tumours
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy and in combination with pembrolizumab in advanced solid tumours that have progressed following SoC treatment.
- Trial name
- KEYNOTE-E86 (NCT04907851)
- Testing
- RXC004, Denosumab, pembrolizumab
- Where
- 13 sites in Australia, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Redx Pharma Ltd
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.